12 studies found for:    17021318 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Treat and Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
2 Completed
Has Results
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: ranibizumab
3 Completed
Has Results
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: ranibizumab
4 Withdrawn Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Conditions: Sickle Cell Anemia;   Retinopathy
Intervention: Drug: Ranibizumab
5 Unknown  Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
Condition: Neovascular Age-related Macular Degeneration
Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection
6 Recruiting Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Condition: Radiation Retinopathy
Interventions: Drug: 0.5 mg ranibizumab;   Procedure: Targeted Retinal Photocoagulation
7 Not yet recruiting Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
Condition: Neovascular Age-related Macular Degeneration of All Subtypes
Intervention: Procedure: Intravitreal injection
8 Recruiting Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Conditions: Exudative Age-related Macular Degeneration;   Polypoidal Choroidal Vasculopathy
Intervention: Drug: aflibercept
9 Active, not recruiting Study for Recalcitrant Age Related Macular Degeneration
Condition: Age Related Macular Degeneration
Intervention: Drug: aflibercept 2.0 mg
10 Terminated Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Ranibizumab (Lucentis)
11 Completed A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
12 Unknown  Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Conditions: Macular Degeneration;   Visual Acuity
Intervention: Drug: Ranibizumab

Indicates status has not been verified in more than two years